Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NSD2 | O96028 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14861613 | 1.00 | ALDH1A1 (0.32) | ALDH1A1MAPTGAAHTTKDM4E | |
| SCHEMBL22412419 | 0.79 | RAB9A (0.46) | ALDH1A1MAPTGAAHTTKDM4E | |
| SCHEMBL22412417 | 0.79 | RAB9A (0.46) | ALDH1A1MAPTGAAHTTKDM4E | |
| SCHEMBL14862429 | 0.71 | ALDH1A1 (0.35) | ALDH1A1MAPTGAAHTT | |
| SCHEMBL14869789 | 0.71 | ALDH1A1 (0.35) | ALDH1A1MAPTGAAHTT | |
| SCHEMBL17240191 | 0.67 | NPSR1 (0.33) | — | |
| SCHEMBL15884707 | 0.67 | NPSR1 (0.33) | — | |
| SCHEMBL18420998 | 0.66 | MAPT (0.39) | ALDH1A1MAPTHTTKDM4E | |
| SCHEMBL26643771 | 0.66 | — | — | |
| SCHEMBL22412533 | 0.65 | KDM4E (0.47) | ALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067930-B2 | 2-oxo-piperidinyl derivatives | UCB PHARMA, S.A. (BE) | 2015-06-30 | — | — | US | disclosed |
| US-9067930-B2 | 2-oxo-piperidinyl derivatives | UCB PHARMA, S.A. (BE) | 2015-06-30 | — | — | US | disclosed |
| US-9067930-B2 | 2-oxo-piperidinyl derivatives | UCB PHARMA, S.A. (BE) | 2015-06-30 | — | — | US | disclosed |
| EP-2766353-B1 | 2-OXO-PIPERIDINYL DERIVATIVES | UCB PHARMA SA (BE) | 2015-06-17 | — | — | EP | disclosed |
| EP-2766353-B1 | 2-OXO-PIPERIDINYL DERIVATIVES | UCB PHARMA SA (BE) | 2015-06-17 | — | — | EP | disclosed |
| US-20150011526-A1 | 2-Oxo-Piperidinyl Derivatives | UCB BIOPHARMA SPRL (BE) | 2015-01-08 | — | — | US | disclosed |
| US-20150011526-A1 | 2-Oxo-Piperidinyl Derivatives | UCB BIOPHARMA SPRL (BE) | 2015-01-08 | — | — | US | disclosed |
| US-20150011526-A1 | 2-Oxo-Piperidinyl Derivatives | UCB BIOPHARMA SPRL (BE) | 2015-01-08 | — | — | US | disclosed |
| WO-2013053725-A1 | 2-OXO-PIPERIDINYL DERIVATIVES | UCB PHARMA, S.A. (BE) | 2013-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011526-A1 | 2-Oxo-Piperidinyl Derivatives | CYP3A4, CYP2C19, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ALDH1A1 816/4885MAPT 2122/4885GAA 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.